434 completed, 38 unknown, 32 recruiting, 28 terminated. 169 Phase 4, 120 Phase 2, 104 Phase 3, 69 Phase 1, 55 Not applicable.
Follow this drug Literature Review of Influenza Vaccines trials Research Report on Influenza Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal LAIV Mucosal Immunity Examination Live Attenuated Influenza Vaccine - Impact of Vaccination | Phase 4 | Not yet recruiting | University of Maryland, Baltimore | 25 | 2027-02-01 | 2026-09-03 |
| Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore High-dose influenza vaccine, Standard-dose influenza vaccine - Influenza | Phase 4 | Not yet recruiting | Tan Tock Seng Hospital | 150 | 2026-11-01 | 2026-10-20 |
| Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults Standard dose influenza vaccine, MF59 adjuvanted influenza vaccine, High dose influenza vaccine - Influenza Vaccination, Older Adults (65 Years and Older) | Phase 4 | Recruiting | Korea University Guro Hospital | 180 | 2026-09-21 | 2026-09-24 |
| Inflammation and Medical Provider Attitudes, Cognition, and Treatment Decisions Study Influenza vaccine, Placebo - Decision-Making, Patient Care | Phase 2 | Recruiting | University of Arkansas, Fayetteville | 210 | 2026-09-01 | 2026-09-30 |
| Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study. - Influenza (Healthy Volunteers) | Phase 1 | Recruiting | Dalhousie University | 32 | 2026-06-01 | 2026-08-27 |
| Vaccination Response Modulation With a Targeted Rapamycin Protocol Study Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), RSV vaccine (Pfizer Abrysvo) - Vaccine Immune Response, Haemodialysis Patients | Phase 2 | Not yet recruiting | Central Adelaide Local Health Network Incorporated | 60 | 2026-05-01 | 2026-05-14 |
| Structured Review: To Optimise Management and Prevent Harm in COPD Sputum sample, Venepuncture, Lung function test - COPD | Not applicable | Recruiting | Northumbria Healthcare NHS Foundation Trust | 96 | 2026-03-11 | 2026-04-23 |
| Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide - Malignant Pleural Mesotheliomas | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-06 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma EB-DTNB-NK, Fludarabine, Cyclophosphamide - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-03-30 |
| Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme Trial Influenza and Tdap Vaccination Educational and Learning Module - Vaccination Uptake, Knowledge | Not applicable | Recruiting | Universiti Putra Malaysia | 351 | 2026-01-13 | 2026-05-01 |
| Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses Flu Vaccine, Biological samples - Volunteers, Flu Vaccine | Phase 4 | Active not recruiting | Centre Hospitalier Universitaire de Saint Etienne | 30 | 2025-12-05 | 2025-12-30 |
| Influenza Vaccination After Acute Coronary Syndrome Influenza vaccine, Placebo - Acute Coronary Syndromes (ACS) | Not applicable | Recruiting | Tongji Hospital | 6620 | 2025-12-03 | 2026-01-13 |
| Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions Influenza vaccination - Myocardial Infarction, Decompensated Chronic Heart Failure | Phase 4 | Recruiting | Wroclaw Medical University | 400 | 2025-11-12 | 2026-06-01 |
| A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo - Healthy Participants | Phase 1 | Active not recruiting | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 710 | 2025-11-08 | 2026-10-16 |
| Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults Standard-Dose Influenza Vaccine, MF59-Adjuvanted Influenza Vaccine, High-Dose Influenza Vaccine - Influenza, Influenza Vaccines | Phase 4 | Completed | Korea University Guro Hospital | 121 | 2025-10-25 | 2026-09-04 |
| The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study Live attenuated influenza vaccine, Placebo nasal spray, recombinant hemagglutinin influenza vaccine - Influenza | Phase 4 | Active not recruiting | The University of Hong Kong | 600 | 2025-10-01 | 2026-05-15 |
| Woodsmoke Exposure, Influenza Infection, and Nasal Immunity LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection - Smoke Exposure, Influenza | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 112 | 2025-09-26 | 2026-04-30 |
| High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine - Immunization; Infection|Transplantation Infection|Influenza, Influenza | Phase 2 | Recruiting | Vanderbilt University Medical Center | 60 | 2025-09-17 | 2026-10-21 |
| Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose) Influenza Vaccine (Split Virion), Inactivated (High Dose), Influenza Vaccine (Split Virion), Inactivated - Influenza | Phase 1 | Completed | Sinovac Biotech Co., Ltd | 50 | 2025-08-21 | 2026-09-23 |
| VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu) - Older Patients, Myeloid Malignancies | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 160 | 2025-07-15 | 2025-07-04 |
Showing 20 of 560. Sign in to see all of them.
Influenza, Human (424) · COVID-19 (18) · Infections (12) · Orthomyxoviridae Infections (11) · Virus Diseases (11) · Influenza in Birds (8) · Neoplasms (8) · Heart Failure (5) · Inflammatory Bowel Diseases (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Myocardial Infarction (5) · Pneumococcal Infections (5) · Pneumonia (5) · Colorectal Neoplasms (4) · Leukemia, Myeloid, Acute (4)
Sanofi Pasteur, a Sanofi Company (67) · National Institute of Allergy and Infectious Diseases (NIAID) (27) · GlaxoSmithKline (19) · Stanford University (16) · Seqirus (11) · Sinovac Biotech Co., Ltd (11) · Duke University (10) · Novartis Vaccines (10) · University of Wisconsin, Madison (10) · Sanofi (9) · Emory University (8) · Novartis (8) · MedImmune LLC (7) · Vanderbilt University Medical Center (7) · Insight Therapeutics, LLC (5)
United States (288) · China (40) · Canada (37) · Australia (20) · United Kingdom (16) · Italy (15) · South Korea (15) · Spain (15) · Finland (14) · France (13) · Belgium (11) · Germany (10) · Netherlands (10) · Philippines (10) · Puerto Rico (10)
Cornelia Dekker, MD (7) · Cornelia L Dekker, MD (6) · Mary S Hayney, PharmD (6) · Xiaosong He, PhD (6) · Stefan Gravenstein, MD, MPH (5) · Harry Greenberg, MD (4) · Stephen Quake, PhD (4)
PMID 28963118, PMID 29465480, PMID 18420314, PMID 19588665, PMID 21615847, PMID 22906937, PMID 25148380, PMID 25184864, PMID 26787832, PMID 28325769, PMID 28369198, PMID 29253090, PMID 29706550, PMID 31582202, PMID 38743692, PMID 40237463, PMID 10439494, PMID 10471173, PMID 10727545, PMID 10910448, PMID 11169012, PMID 11742917, PMID 12819247, PMID 12915495, PMID 13679482, PMID 14655190, PMID 14706961, PMID 15195237, PMID 15694506, PMID 16140685, PMID 16220095, PMID 16372666, PMID 16825330, PMID 17395338, PMID 17698577, PMID 17728708, PMID 17908277, PMID 18289372, PMID 18339461, PMID 18401289, PMID 18425905, PMID 18552253, PMID 18701615, PMID 19064822, PMID 19149900, PMID 19508159, PMID 19561422, PMID 19618288, PMID 19673652, PMID 19716456
U19AI057229 (11), 2009 (6), 2015 (4), 2008 (3), 2019 (3), U19AI090019 (3), 2017 (2), 2018 (2), 2023 (2), P30CA012197 (2), 2025 (1), 272201400005C-P00019-9999-4 (1), OT2HL158287 (1), P01CA225618 (1), P30CA033572 (1)